Literature DB >> 31108196

Ongoing Challenges with Clinical Assessment of Nodal Status in T1 Esophageal Adenocarcinoma.

Tamar B Nobel1, Arianna Barbetta2, Meier Hsu3, Kay See Tan3, Smita Sihag2, Manjit S Bains2, David R Jones2, Daniela Molena4.   

Abstract

BACKGROUND: Endoscopic mucosal resection (EMR) has emerged as an esophageal-preserving treatment for T1 esophageal adenocarcinoma (EAC); however, only patients with negligible risk of lymph node metastasis (LNM) are eligible. Reliable clinical diagnostic tools for LNM are lacking, as such, several risk assessment scores have been developed. The purpose of this study was to externally validate 2 previously published risk scores (Lee and Weksler) for clinical prediction of LNM in T1 EAC patients.
METHODS: In adherence with the Lee and Weksler scores, esophagectomy patients with pathologic T1 EAC were identified. Sub-analysis was performed in patients with clinical T1 based on EMR. Predictive accuracy of the scores was evaluated by calculating the area under the curve of the receiver operating characteristic curve and calibration plots. The areas under the curves were compared using Venkatraman's test for paired receiver operating characteristic curves.
RESULTS: Of 233 patients identified who met study criteria for external validation, 3 T1a and 32 T1b patients had LNM. The receiver operating characteristic curves demonstrated comparable high predictive and discriminatory capabilities with areas under the curves of 0.832 and 0.824 for the Lee and Weksler scores, respectively (p = 0.750). Results were more variable for the EMR cohort. Based on the risk thresholds defined by each score, the false-positive rate compared against the pathologic LNM status were 73% and 56% for Lee and Weksler, with 3% false negatives in the latter. On EMR, the false-positive rates were 70% and 50% for Lee and Weksler, with no false negatives.
CONCLUSIONS: Both scoring systems demonstrated good discriminatory ability and predictive accuracy for LNM, but the defined thresholds resulted in a high false-positive rate. A better scoring system based on clinical characteristics is needed to better identify patients with local disease.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2019        PMID: 31108196      PMCID: PMC6830507          DOI: 10.1016/j.jamcollsurg.2019.04.032

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  19 in total

Review 1.  Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer.

Authors:  H L van Westreenen; M Westerterp; P M M Bossuyt; J Pruim; G W Sloof; J J B van Lanschot; H Groen; J Th M Plukker
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

Review 2.  Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review.

Authors:  Srinivas-R Puli; Jyotsna-Bk Reddy; Matthew-L Bechtold; Daphne Antillon; Jamal-A Ibdah; Mainor-R Antillon
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

3.  The role of positron emission tomography in esophageal cancer.

Authors:  Gary Y Yang; Timothy D Wagner; Blair A Jobe; Charles R Thomas
Journal:  Gastrointest Cancer Res       Date:  2008-01

4.  Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system.

Authors:  Lawrence Lee; Ulrich Ronellenfitsch; Wayne L Hofstetter; Gail Darling; Timo Gaiser; Christiane Lippert; Sebastien Gilbert; Andrew J Seely; David S Mulder; Lorenzo E Ferri
Journal:  J Am Coll Surg       Date:  2013-05-06       Impact factor: 6.113

5.  Surveillance Implications of Recurrence Patterns in Early Node-Negative Esophageal Adenocarcinoma.

Authors:  Tamar B Nobel; Jennifer Livschitz; Xin Xin Xing; Arianna Barbetta; Meier Hsu; Kay See Tan; Smita Sihag; David R Jones; Daniela Molena
Journal:  Ann Thorac Surg       Date:  2019-07-16       Impact factor: 4.330

6.  Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection.

Authors:  Hubert J Stein; Marcus Feith; Bjorn L D M Bruecher; Jorg Naehrig; Mario Sarbia; J Rudiger Siewert
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

7.  Using the National Cancer Database to create a scoring system that identifies patients with early-stage esophageal cancer at risk for nodal metastases.

Authors:  Benny Weksler; Kevin F Kennedy; Jennifer L Sullivan
Journal:  J Thorac Cardiovasc Surg       Date:  2017-07-29       Impact factor: 5.209

8.  Prognostic risk factors of early esophageal adenocarcinomas.

Authors:  Dietmar Lorenz; Judith Origer; Michael Pauthner; Florian Graupe; Annette Fisseler-Eckhoff; Manfred Stolte; Oliver Pech; Christian Ell
Journal:  Ann Surg       Date:  2014-03       Impact factor: 12.969

9.  Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas.

Authors:  H Q Peng; B D Greenwald; F R Tavora; E Kling; P Darwin; W H Rodgers; A Berry
Journal:  Diagn Cytopathol       Date:  2008-05       Impact factor: 1.582

10.  Prediction of lymph node status in superficial esophageal carcinoma.

Authors:  Ermanno Ancona; Sabrina Rampado; Mauro Cassaro; Giorgio Battaglia; Alberto Ruol; Carlo Castoro; Giuseppe Portale; Francesco Cavallin; Massimo Rugge
Journal:  Ann Surg Oncol       Date:  2008-08-26       Impact factor: 5.344

View more
  2 in total

1.  Infiltration Depth is the Most Relevant Risk Factor for Overall Metastases in Early Esophageal Adenocarcinoma.

Authors:  Christina Oetzmann von Sochaczewski; Thomas Haist; Michael Pauthner; Markus Mann; Susanne Braun; Christian Ell; Dietmar Lorenz
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

2.  Defining low-risk lesions in early-stage esophageal adenocarcinoma.

Authors:  Smita Sihag; Sergio De La Torre; Meier Hsu; Tamar Nobel; Kay See Tan; Hans Gerdes; Pari Shah; Manjit Bains; David R Jones; Daniela Molena
Journal:  J Thorac Cardiovasc Surg       Date:  2020-11-24       Impact factor: 6.439

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.